10mg
Pharmaceutical-grade melanocortin receptor agonist peptide studied for its role in central nervous system arousal pathways in both sexes. It is FDA-approved under the brand name Vyleesi for the treatment of premenopausal hypoactive sexual desire disorder (HSDD).
The compound acts centrally via MC3R and MC4R receptor activity, representing a mechanism distinct from peripheral PDE5 inhibitors. Independently verified by Analiza Białek with a reported purity of 99%, with finished vial content confirmed at 10.06 mg against a 10 mg label claim.
